Novel circulating tumor cell‑detection chip combining conventional podoplanin and EGFR antibodies for all histological malignant pleural mesothelioma

Kanayama,Masatoshi; Oyama,Rintaro; Mori,Masataka; Taira,Akihiro; Shinohara,Shinji; Kuwata,Taiji; Takenaka,Masaru; Yoneda,Kazue; Kuroda,Koji; Ohnaga,Takashi; Kato,Yukinari; Tanaka,Fumihiro

doi:10.3892/ol.2021.12783

Novel circulating tumor cell‑detection chip combining conventional podoplanin and EGFR antibodies for all histological malignant pleural mesothelioma

Authors:
- Masatoshi Kanayama
- Rintaro Oyama
- Masataka Mori
- Akihiro Taira
- Shinji Shinohara
- Taiji Kuwata
- Masaru Takenaka
- Kazue Yoneda
- Koji Kuroda
- Takashi Ohnaga
- Yukinari Kato
- Fumihiro Tanaka
View Affiliations

Affiliations: Second Department of Surgery, University of Occupational and Environmental Health, Kitakyushu, Fukuoka 807‑8555, Japan, Central Research Laboratories, Toyama Industrial Technology Center, Takaoka, Toyama 933‑0981, Japan, Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Miyagi 980‑8575, Japan
Published online on: May 11, 2021 https://doi.org/10.3892/ol.2021.12783
Article Number: 522
Copyright : © Kanayama et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In our previous study, a microfluidic system was developed based on podoplanin detection for capturing circulating tumor cells (CTCs), derived from malignant pleural mesothelioma (MPM). However, non‑epithelioid MPM shows low podoplanin protein expression compared with that in epithelioid MPM; thus, some CTC populations may be missed. To overcome this limitation, a new CTC‑detection chip was developed by combining the conventional podoplanin antibody (clone: NZ‑1.2) with an epidermal growth factor receptor (EGFR)‑targeted antibody (cetuximab). The cell‑capture efficiency of the Cocktail‑chip reached 100% in all the histological MPM cell lines. The median CTC‑counts from 19 patients with MPM (epithelioid/non‑epithelioid: 10/9) with the NZ‑1.2‑ and Cocktail‑chips were 1 and 3 (P=0.311) in 1 ml peripheral blood, 1.5 and 2 (P=0.332) in epithelioid MPM, and 1 and 3 (P=0.106) in non‑epithelioid MPM, respectively. Overall, the Cocktail‑chip showed an improved ability to detect more CTCs in patients with non‑epithelioid MPM compared with that in the conventional NZ‑1.2‑chip, showing non‑significant, but higher CTC detection. Furthermore, CTC‑counts, determined using the Cocktail‑chip were significantly correlated with the clinical stage of non‑epithelioid MPM. In epithelioid MPM, the Cocktail‑chip achieved a CTC‑detection efficiency equivalent to that in the conventional NZ‑1.2‑chip. The Cocktail‑chip enabled sensitive CTC detection of all histological MPM, including the non‑epithelioid subtype, which may provide a foundation for the diagnosis, treatment, and prognosis of MPM progression.

View Figures

View References

1	Tanaka F, Yoneda K and Hasegawa S: Circulating tumor cells (CTCs) in lung cancer: Current status and future perspectives. Lung Cancer (Auckl). 1:77–84. 2010.PubMed/NCBI
2	Alix-Panabières C, Riethdorf S and Pantel K: Circulating tumor cells and bone marrow micrometastasis. Clin Cancer Res. 14:5013–5021. 2008. View Article : Google Scholar
3	Siravegna G, Marsoni S, Siena S and Bardelli A: Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. 14:531–548. 2017. View Article : Google Scholar : PubMed/NCBI
4	Cabel L, Proudhon C, Gortais H, Loirat D, Coussy F, Pierga JY and Bidard FC: Circulating tumor cells: Clinical validity and utility. Int J Clin Oncol. 22:421–430. 2017. View Article : Google Scholar : PubMed/NCBI
5	Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, Tibbe AG, Uhr JW and Terstappen LW: Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 10:6897–6904. 2004. View Article : Google Scholar : PubMed/NCBI
6	Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, et al: Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 351:781–791. 2004. View Article : Google Scholar : PubMed/NCBI
7	Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse M, Mitchell E, Miller MC, et al: Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 26:3213–3221. 2008. View Article : Google Scholar : PubMed/NCBI
8	de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, Doyle GV, Terstappen LW, Pienta KJ and Raghavan D: Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 14:6302–6309. 2008. View Article : Google Scholar : PubMed/NCBI
9	Krebs MG, Sloane R, Priest L, Lancashire L, Hou JM, Greystoke A, Ward TH, Ferraldeschi R, Hughes A, Clack G, et al: Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol. 29:1556–1563. 2011. View Article : Google Scholar : PubMed/NCBI
10	Miller MC, Doyle GV and Terstappen LW: Significance of Circulating Tumor Cells Detected by the CellSearch System in Patients with Metastatic Breast Colorectal and Prostate Cancer. J Oncol. 2010:6174212010. View Article : Google Scholar : PubMed/NCBI
11	Tanaka F, Yoneda K, Kondo N, Hashimoto M, Takuwa T, Matsumoto S, Okumura Y, Rahman S, Tsubota N, Tsujimura T, et al: Circulating tumor cell as a diagnostic marker in primary lung cancer. Clin Cancer Res. 15:6980–6986. 2009. View Article : Google Scholar : PubMed/NCBI
12	Yoneda K, Tanaka F, Kondo N, Hashimoto M, Takuwa T, Matsumoto S, Okumura Y, Tsubota N, Sato A, Tsujimura T, et al: Circulating tumor cells (CTCs) in malignant pleural mesothelioma (MPM). Ann Surg Oncol. 21 (Suppl 4):S472–S480. 2014. View Article : Google Scholar : PubMed/NCBI
13	Ohnaga T, Shimada Y, Moriyama M, Kishi H, Obata T, Takata K, Okumura T, Nagata T, Muraguchi A and Tsukada K: Polymeric microfluidic devices exhibiting sufficient capture of cancer cell line for isolation of circulating tumor cells. Biomed Microdevices. 15:611–616. 2013. View Article : Google Scholar : PubMed/NCBI
14	Chikaishi Y, Yoneda K, Ohnaga T and Tanaka F: EpCAM-independent capture of circulating tumor cells with a ‘universal CTC-chip’. Oncol Rep. 37:77–82. 2017. View Article : Google Scholar : PubMed/NCBI
15	Yoneda K, Kuwata T, Chikaishi Y, Mori M, Kanayama M, Takenaka M, Oka S, Hirai A, Imanishi N, Kuroda K, et al: Detection of circulating tumor cells with a novel microfluidic system in malignant pleural mesothelioma. Cancer Sci. 110:726–733. 2019. View Article : Google Scholar : PubMed/NCBI
16	Kuwata T, Yoneda K, Mori M, Kanayama M, Kuroda K, Kaneko MK, Kato Y and Tanaka F: Detection of circulating tumor cells (CTCs) in malignant pleural mesothelioma (MPM) with the ‘Universal’ CTC-Chip and an anti-podoplanin antibody NZ-1.2. Cells. 9:8882020. View Article : Google Scholar : PubMed/NCBI
17	Husain AN, Colby TV, Ordóñez NG, Allen TC, Attanoos RL, Beasley MB, Butnor KJ, Chirieac LR, Churg AM, Dacic S, et al: Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group. Arch Pathol Lab Med. 142:89–108. 2018. View Article : Google Scholar : PubMed/NCBI
18	Ordóñez NG: D2-40 and podoplanin are highly specific and sensitive immunohistochemical markers of epithelioid malignant mesothelioma. Hum Pathol. 36:372–380. 2005. View Article : Google Scholar
19	Hinterberger M, Reineke T, Storz M, Weder W, Vogt P and Moch H: D2-40 and calretinin - a tissue microarray analysis of 341 malignant mesotheliomas with emphasis on sarcomatoid differentiation. Mod Pathol. 20:248–255. 2007. View Article : Google Scholar : PubMed/NCBI
20	Padgett DM, Cathro HP, Wick MR and Mills SE: Podoplanin is a better immunohistochemical marker for sarcomatoid mesothelioma than calretinin. Am J Surg Pathol. 32:123–127. 2008. View Article : Google Scholar : PubMed/NCBI
21	Salomon DS, Brandt R, Ciardiello F and Normanno N: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 19:183–232. 1995. View Article : Google Scholar : PubMed/NCBI
22	Destro A, Ceresoli GL, Falleni M, Zucali PA, Morenghi E, Bianchi P, Pellegrini C, Cordani N, Vaira V, Alloisio M, et al: EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations. Lung Cancer. 51:207–215. 2006. View Article : Google Scholar : PubMed/NCBI
23	Dazzi H, Hasleton PS, Thatcher N, Wilkes S, Swindell R and Chatterjee AK: Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody. Br J Cancer. 61:924–926. 1990. View Article : Google Scholar : PubMed/NCBI
24	Govindan R, Ritter J and Suppiah R: EGFR and HER-2 overexpression in malignant mesothelioma. Proc Am Soc Clin Oncol. 20:31062001.
25	Govindan R, Kratzke RA, Herndon JE II, Niehans GA, Vollmer R, Watson D, Green MR and Kindler HL: Cancer and Leukemia Group B (CALGB 30101): Gefitinb in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res. 11:2300–2304. 2005. View Article : Google Scholar : PubMed/NCBI
26	Ohnaga T, Takei Y, Nagata T and Shimada Y: Highly efficient capture of cancer cells expressing EGFR by microfluidic methods based on antigen-antibody association. Sci Rep. 8:120052018. View Article : Google Scholar : PubMed/NCBI
27	Kaji C, Tsujimoto Y, Kato Kaneko M, Kato Y and Sawa Y: Immunohistochemical Examination of Novel Rat Monoclonal Antibodies against Mouse and Human Podoplanin. Acta Histochem Cytochem. 45:227–237. 2012. View Article : Google Scholar : PubMed/NCBI
28	Rice D, Rusch V, Pass H, Asamura H, Nakano T, Edwards J, Giroux DJ, Hasegawa S, Kernstine KH, Waller D, et al International Association for the Study of Lung Cancer International Staging Committee and the International Mesothelioma Interest Group, : Recommendations for uniform definitions of surgical techniques for malignant pleural mesothelioma: A consensus report of the international association for the study of lung cancer international staging committee and the international mesothelioma interest group. J Thorac Oncol. 6:1304–1312. 2011. View Article : Google Scholar : PubMed/NCBI
29	Habougit C, Trombert-Paviot B, Karpathiou G, Casteillo F, Bayle-Bleuez S, Fournel P, Vergnon JM, Tiffet O, Péoc'h M and Forest F: Histopathologic features predict survival in diffuse pleural malignant mesothelioma on pleural biopsies. Virchows Arch. 470:639–646. 2017. View Article : Google Scholar : PubMed/NCBI